Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
07/19/17
These Data, Combined with Positive Results from Two Phase 3 Efficacy Studies, Support NDA Filing Planned for Fourth Quarter of 2017 DUBLIN, IRELAND, Hertfordshire, england and pittsburgh – July 19, 2017 – Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V.
06/05/17

VIBATIV (telavancin) Demonstrates Greater in vitro Activity Compared to Competitor Antibiotics Against Range of Challenging Infection Types

05/23/17

Presentations Review Detailed Efficacy and Safety Data from Two Replicate Pivotal Phase 3 Studies; Report Prevalence of COPD Patients with Low Peak Inspiratory Flow Rate in Ongoing 12-Month Phase 3 Safety Trial

05/17/17

Presentations Will Include Detailed Efficacy and Safety Data from Two Replicate Pivotal Phase 3 Studies

05/09/17

Key Program Milestones Anticipated in Remainder of 2017 and 2018

05/02/17
DUBLIN , May 2, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced that it will release financial results for the period ended March 31, 2017 after market close on Tuesday, May 9, 2017 .
04/27/17
DUBLIN , April 27, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will present a corporate overview at the Deutsche Bank 42nd Annual Health Care Conference on Thursday, May 4, 2017 at 8:00 a.m.
04/25/17

VIBATIV (telavancin) Demonstrates Greater in vitro and in vivo Potency Compared to Competitor Antibiotics Against Difficult-to-Treat Staphylococcus aureus Pathogens including MRSA and MSSA

04/24/17

Clinical Response Rates with VIBATIV® (telavancin) Treatment Range from 58 - 75% for Patients with Complicated Skin and Skin Structure Infections, Bone and Joint Infections, or Lower Respiratory Tract Infections

04/18/17

Preliminary Data from TOUR Highlights Positive Clinical Response Rates Across Several Difficult-to-Treat Infection Types<br>Additional VIBATIV Presentations Demonstrate in vitro and in vivo Potency Against Difficult-to-Treat Staphylococcus aureus Pathogens including Challenging MRSA and MSSA Isolates